Nazione: Australia
Lingua: inglese
Fonte: Department of Health (Therapeutic Goods Administration)
rifampicin, Quantity: 150 mg
Sanofi-Aventis Australia Pty Ltd
Rifampicin
Capsule
Excipient Ingredients: maize starch; magnesium stearate; Gelatin; erythrosine; titanium dioxide; indigo carmine
Oral
100 capsules
(S4) Prescription Only Medicine
Tuberculosis. In the initial treatment and in re-treatment of patients with tuberculosis, RIFADIN must be used in conjunction with at least one other antituberculosis drug. Leprosy. In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal disease. Prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (RIFADIN is not indicated for the treatment of meningococcal infections). Haemophilus influenzae. Prophylaxis of household contacts of patients with H. influenzae type B.
Visual Identification: Blue cap, red body capsules each marked "R-150" containing a brick-red coloured powder; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2015-06-17
RIFADIN ® ORAL R i f a d i n ® O R A L CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about taking this medicine, speak to your doctor or pharmacist. 1. WHY AM I TAKING RIFADIN? Rifadin contains the active ingredient rifampicin. Rifadin is an antibiotic taken with other medicines to treat tuberculosis and is taken to treat leprosy. It is also taken to prevent meningococcal disease and infections caused by _Haemophilus Influenza_ Type B. For more information, see Section 1. Why am I taking Rifadin? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I TAKE RIFADIN? Do not take Rifadin if you have ever had an allergic reaction to Rifadin or any of the ingredients listed at the end of the CMI. Do not take Rifadin if you have jaundice. Do not take Rifadin if you are taking saquinavir or ritonavir. These are medicines used to treat AIDS and HIV. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING OR PLANNING TO BREASTFEED. For more information, see Section 2. What should I know before I take Rifadin? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with Rifadin and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I TAKE RIFADIN? Follow the instructions provided when Rifadin was prescribed, including the number of days it should be taken. More instructions can be found in Section 4. How do I take Rifadin? in the full CMI. 5. WHAT SHOULD I KNOW WHILE TAKING RIFADIN? THINGS YOU SHOULD DO • Remind any doctor, dentist, surgeon, or pharmacist you visit that you are taking Rifadin. • You should see your doctor monthly for a check-up. • Continue taking Rifadin exactly as prescribed by your doctor. • If you have a blood or urine test, tell your doctor you are taking Rifadin. • If you are about to be started on a new medicine, including oral contr Leggi il documento completo
rifadin-ccdsv17-piv18-17feb22 Page 1 of 17 AUSTRALIAN PRODUCT INFORMATION – RIFADIN ® (RIFAMPICIN) 1 NAME OF THE MEDICINE Rifampicin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Rifadin 150 mg capsules contain 150 mg of rifampicin per capsule. Rifadin 300 mg capsules contain 300 mg of rifampicin per capsule. Rifadin syrup contains 100 mg of rifampicin per 5 mL of syrup. Rifadin IV infusion contains 600 mg rifampicin per vial. Excipients with known effect Capsules: contain sulfites Syrup: contains methyl hydroxybenzoate, propyl hydroxybenzoate, potassium sorbate, sodium metabisulfite and saccharin. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Capsules: 150 mg (blue/red, marked R-150) 300 mg (red, marked R-300) Syrup: 100 mg/5 mL (red, raspberry flavoured) IV infusion: 600 mg (spongy, fragile amorphous red powder) with 10 mL sterile water for injection solvent 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tuberculosis In the initial treatment and in re-treatment of patients with tuberculosis, Rifadin must be used in conjunction with at least one other antituberculosis drug. rifadin-ccdsv17-piv18-17feb22 Page 2 of 17 Leprosy In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. As an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. Meningococcal Disease Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (Rifadin is not indicated for the treatment of meningococcal infections). Haemophilus Influenzae Prophylaxis of household contacts of patients with _H. influenzae_ type B. 4.2 DOSE AND METHOD OF ADMINISTRATION ORAL It is recommended that oral Rifadin be administered once daily, on an em Leggi il documento completo